ASX:CUVBiotechs
Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential
Clinuvel Pharmaceuticals (ASX:CUV) has started dosing patients in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform. This marks its first next-generation delivery technology to enter formal preclinical testing.
See our latest analysis for Clinuvel Pharmaceuticals.
The VLRX-L preclinical milestone comes as the share price sits at A$12.75, with a 1-day share price return of 4.25% and a 90-day share price return of 10.29%, while the 1-year total shareholder...